Implication of JAK1, JAK2, and JAK3 in the Realization of Proliferation and Differentiation Potential of Mesenchymal Progenitor Cells In Vitro

被引：3
|
作者：
Zyuz'kov, G. N. [1 ,2 ]
Zhdanov, V. V. [1 ]
Udut, E. V. [1 ]
Miroshnichenko, L. A. [1 ]
Simanina, E. V. [1 ]
Polyakova, T. Yu. [1 ]
Chaikovskii, A. V. [1 ]
Stavrova, L. A. [1 ]
Udut, V. V. [2 ]
Agafonov, V. I. [1 ]
Burmina, Ya. V. [1 ]
Danilets, M. G. [1 ]
Minakova, M. Yu. [1 ]
Dygai, A. M. [1 ]
机构：
[1] ED Goldberg Res Inst Pharmacol & Regenerat Med, Tomsk, Russia
[2] Natl Res Tomsk State Univ, Tomsk, Russia
来源：
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2016年 / 161卷 / 02期
关键词：
signal pathways; JAK kinases; progenitor cells; regenerative medicine; pharmacological control; COLONY-STIMULATING FACTOR; FUNCTIONAL STIMULATION; ALKALOID SONGORINE; PRECURSOR CELLS; BRAIN ISCHEMIA; HYALURONIDASE; MECHANISMS; STATS; Z77;
D O I：
10.1007/s10517-016-3381-7
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Involvement of individual JAK kinases in the realization of growth potential of mesenchymal progenitor cells was examined in vitro. Important role of JAK2 and JAK3 in determining the initial level of mitotic activity of progenitor cells was established. The yield of fibroblast CFUF was suppressed under the effect of specific inhibitors of JAK kinases. Blockade of JAK3 increased the rate of progenitor element differentiation. JAK1 had no effect on proliferation and differentiation status of progenitor cells.
引用
收藏
页码：224 / 227
页数：4
相关论文
共 50 条
  • [41] A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses
    Kohlhuber, F
    Rogers, NC
    Watling, D
    Feng, J
    Guschin, D
    Briscoe, J
    Witthuhn, BA
    Kotenko, SV
    Pestka, S
    Stark, GR
    Ihle, JN
    Kerr, IM
    MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (02) : 695 - 706
  • [42] JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis
    Wu, Junchao
    Li, Lisha
    Zhu, Quangang
    Zhang, Tingrui
    Miao, Fengze
    Cui, Zhen
    Dong, Guoqiang
    Tai, Zongguang
    Chen, Zhongjian
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 171
  • [43] Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
    Mesa, Ruben A.
    IDRUGS, 2010, 13 (06) : 394 - 403
  • [44] The JAK1/JAK2 Inhibitor Ruxolitinib Substantially Affects NK Cell Biology
    Schoenberg, Kathrin
    Rudolph, Janna
    Cornez, Isabelle
    Brossart, Peter
    Wolf, Dominik
    BLOOD, 2013, 122 (21)
  • [45] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    Pardanani, A.
    Laborde, R. R.
    Lasho, T. L.
    Finke, C.
    Begna, K.
    Al-Kali, A.
    Hogan, W. J.
    Litzow, M. R.
    Leontovich, A.
    Kowalski, M.
    Tefferi, A.
    LEUKEMIA, 2013, 27 (06) : 1322 - 1327
  • [46] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    A Pardanani
    R R Laborde
    T L Lasho
    C Finke
    K Begna
    A Al-Kali
    W J Hogan
    M R Litzow
    A Leontovich
    M Kowalski
    A Tefferi
    Leukemia, 2013, 27 : 1322 - 1327
  • [47] Variants in the JAK1 and JAK2 genes in the risk and prognosis of patients with cutaneous melanoma
    Carvalho, B. F.
    Gomez, G. V. B.
    Lourenco, G. J.
    Moraes, A. M. D.
    Lima, C. S. Passos
    ANNALS OF ONCOLOGY, 2019, 30 : 14 - 14
  • [48] A transient dephosphorylation of JAK1 and JAK2 characterises the early-phase response of murine erythroleukemia cells to the differentiation inducer hexamethylenebisacetamide
    Arcangeli, A
    Fontana, L
    Crociani, O
    Cherubini, A
    Hofmann, G
    Piccini, E
    Polvani, S
    D'Amico, M
    Carlà, M
    Olivotto, M
    LEUKEMIA, 2000, 14 (12) : 2112 - 2117
  • [49] A transient dephosphorylation of JAK1 and JAK2 characterises the early-phase response of murine erythroleukemia cells to the differentiation inducer hexamethylenebisacetamide
    A Arcangeli
    L Fontana
    O Crociani
    A Cherubini
    G Hofmann
    E Piccini
    S Polvani
    M D'Amico
    M Carlà
    M Olivotto
    Leukemia, 2000, 14 : 2112 - 2117
  • [50] The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells
    Poto, Remo
    Cristinziano, Leonardo
    Criscuolo, Gjada
    Strisciuglio, Caterina
    Palestra, Francesco
    Lagnese, Gianluca
    Di Salvatore, Antonio
    Marone, Gianni
    Spadaro, Giuseppe
    Loffredo, Stefania
    Varricchi, Gilda
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345